Research Analysts Set Expectations for DYAI FY2024 Earnings

Dyadic International, Inc. (NASDAQ:DYAI) – Analysts at HC Wainwright issued their FY2024 earnings estimates for Dyadic International in a research note issued to investors on Wednesday, November 13th. HC Wainwright analyst V. Bernardino expects that the biotechnology company will earn ($0.15) per share for the year. HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Dyadic International’s current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Dyadic International’s Q4 2024 earnings at ($0.01) EPS and FY2025 earnings at ($0.06) EPS.

Dyadic International Price Performance

Dyadic International stock opened at $1.22 on Monday. The company has a debt-to-equity ratio of 1.54, a current ratio of 5.15 and a quick ratio of 5.15. The business has a 50 day simple moving average of $1.12 and a 200-day simple moving average of $1.41. Dyadic International has a 12 month low of $0.93 and a 12 month high of $2.67. The stock has a market capitalization of $36.10 million, a PE ratio of -5.30 and a beta of 0.72.

Dyadic International (NASDAQ:DYAI) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.06. Dyadic International had a negative return on equity of 149.16% and a negative net margin of 188.09%. The firm had revenue of $1.96 million during the quarter, compared to the consensus estimate of $1.05 million. During the same period in the prior year, the business earned ($0.06) EPS.

Hedge Funds Weigh In On Dyadic International

An institutional investor recently raised its position in Dyadic International stock. Chapin Davis Inc. boosted its position in Dyadic International, Inc. (NASDAQ:DYAI) by 2.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 847,301 shares of the biotechnology company’s stock after purchasing an additional 21,000 shares during the period. Chapin Davis Inc. owned about 2.90% of Dyadic International worth $1,254,000 as of its most recent filing with the Securities & Exchange Commission. 27.95% of the stock is owned by hedge funds and other institutional investors.

Dyadic International Company Profile

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.